Maciej Filip Boni

Maciej Filip Boni

Auto-generated profile, based on publicly available information

Maciej Filip Boni

Department of Biology, Pennsylvania State University, University Park, Pennsylvania 16802, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2020 in Nature Microbiology
Verified
Journal Article
Closed access
PDF file
MBMaciej F. Boni
Maciej F. Boni
PLPhilippe Lemey
Philippe Lemey
XJXiaowei Jiang
Xiaowei Jiang
TLTommy Tsan-Yuk Lam
Tommy Tsan-Yuk Lam
BPBlair W. Perry
Blair W. Perry
DRDavid L. Robertson
David L. Robertson

1 June 2007 in Genetics
Verified
Journal Article
Closed access
MBMaciej F Boni
Maciej F Boni
DPDavid Posada
David Posada
MFMarcus W Feldman
Marcus W Feldman
Statistical tests for detecting mosaic structure or recombination among nucleotide sequences usually rely on identifying a pattern or a signal that would be unlikely to appear under clonal reproduction. Dozens of such tests have been described, but many are hampered by long running times, confounding of selection and recombination, and/or inability to isolate the mosaic-producing event. We introduce a test that is exact, nonparametric, rapidly computable, free of the infinite-sites assumption, able to distinguish between recombination and variation in mutation/fixation rates, and able to identify the breakpoints and sequences involved in the mosaic-producing event. Our test considers three sequences at a time: two parent sequences that may have recombined, with one or two breakpoints, to form the third sequence (the child sequence). Excess similarity of the child sequence to a candidate recombinant of the parents is a sign of recombination; we take the maximum value of this excess similarity as our test statistic Δm,n,b. We present a method for rapidly calculating the distribution of Δm,n,b and demonstrate that it has comparable power to and a much improved running time over previous methods, especially in detecting recombination in large data sets.

3 October 2017 in Molecular Biology and Evolution
Verified
Journal Article
Open access
PDF file
HLHa Minh Lam
Ha Minh Lam
OROliver Ratmann
Oliver Ratmann
MBMaciej F Boni
Maciej F Boni
Identifying recombinant sequences in an era of large genomic databases is challenging as it requires an efficient algorithm to identify candidate recombinants and parents, as well as appropriate statistical methods to correct for the large number of comparisons performed. In 2007, a computation was introduced for an exact nonparametric mosaicism statistic that gave high-precision P values for putative recombinants. This exact computation meant that multiple-comparisons corrected P values also had high precision, which is crucial when performing millions or billions of tests in large databases. Here, we introduce an improvement to the algorithmic complexity of this computation from O(mn3) to O(mn2), where m and n are the numbers of recombination-informative sites in the candidate recombinant. This new computation allows for recombination analysis to be performed in alignments with thousands of polymorphic sites. Benchmark runs are presented on viral genome sequence alignments, new features are introduced, and applications outside recombination analysis are discussed.

16 January 2023 in Wellcome Open Research
Verified
Journal Article
Open access
MNMalaria G E N
Malaria G E N
MHMuzamil Mahdi Abdel Hamid
Muzamil Mahdi Abdel Hamid
MAMohamed Hassan Abdelraheem
Mohamed Hassan Abdelraheem
DADesmond Omane Acheampong
Desmond Omane Acheampong
AAAmbroise Ahouidi
Ambroise Ahouidi
RPRob W van der Pluijm
Rob W van der Pluijm
We describe the MalariaGEN Pf7 data resource, the seventh release of Plasmodium falciparum genome variation data from the MalariaGEN network. It comprises over 20,000 samples from 82 partner studies in 33 countries, including several malaria endemic regions that were previously underrepresented. For the first time we include dried blood spot samples that were sequenced after selective whole genome amplification, necessitating new methods to genotype copy number variations. We identify a large number of newly emerging crt mutations in parts of Southeast Asia, and show examples of heterogeneities in patterns of drug resistance within Africa and within the Indian subcontinent. We describe the profile of variations in the C-terminal of the csp gene and relate this to the sequence used in the RTS,S and R21 malaria vaccines. Pf7 provides high-quality data on genotype calls for 6 million SNPs and short indels, analysis of large deletions that cause failure of rapid diagnostic tests, and systematic characterisation of six major drug resistance loci, all of which can be freely downloaded from the MalariaGEN website.

24 February 2021 in Wellcome Open Research
Verified
Journal Article
Open access
PDF file
MNMalaria G E N
Malaria G E N
AAAmbroise Ahouidi
Ambroise Ahouidi
MAMozam Ali
Mozam Ali
JAJacob Almagro-Garcia
Jacob Almagro-Garcia
AAAlfred Amambua-Ngwa
Alfred Amambua-Ngwa
HYHtut Ye
Htut Ye
MalariaGEN is a data-sharing network that enables groups around the world to work together on the genomic epidemiology of malaria. Here we describe a new release of curated genome variation data on 7,000 Plasmodium falciparum samples from MalariaGEN partner studies in 28 malaria-endemic countries. High-quality genotype calls on 3 million single nucleotide polymorphisms (SNPs) and short indels were produced using a standardised analysis pipeline. Copy number variants associated with drug resistance and structural variants that cause failure of rapid diagnostic tests were also analysed. Almost all samples showed genetic evidence of resistance to at least one antimalarial drug, and some samples from Southeast Asia carried markers of resistance to six commonly-used drugs. Genes expressed during the mosquito stage of the parasite life-cycle are prominent among loci that show strong geographic differentiation. By continuing to enlarge this open data resource we aim to facilitate research into the evolutionary processes affecting malaria control and to accelerate development of the surveillance toolkit required for malaria elimination.

16 September 2008 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
MBMaciej F. Boni
Maciej F. Boni
DSDavid L. Smith
David L. Smith
RLRamanan Laxminarayan
Ramanan Laxminarayan
Despite the availability of many drugs and therapies to treat malaria, many countries' national policies recommend using a single first-line therapy for most clinical malaria cases. To assess whether this is the best strategy for the population as a whole, we designed an evolutionary-epidemiological modeling framework for malaria and compared the benefits of different treatment strategies in the context of resistance evolution. Our results show that the population-wide use of multiple first-line therapies (MFT) against malaria yields a better clinical outcome than using a single therapy or a cycling strategy where therapies are rotated, either on a fixed cycling schedule or when resistance levels or treatment failure become too high. MFT strategies also delay the emergence and slow the fixation of resistant strains (phenotypes), and they allow a larger fraction of the population to be treated without trading off future treatment of cases that may be untreatable because of high resistance levels. Earlier papers have noted that cycling strategies have the disadvantage of creating a less temporally variable environment than MFT strategies, making resistance evolution easier for the parasite. Here, we illustrate a second feature of parasite ecology that impairs the performance of cycling policies, namely, that cycling policies degrade the mean fitness of the parasite population more quickly than MFT policies, making it easier for new resistant types to invade and spread. The clinical benefits of using multiple first-line therapies against malaria suggest that MFT policies should play a key role in malaria elimination and control programs.